XRad Therapeutics Announces First Patient Dosed in Phase 1a Clinical Trial of XRD-0394 for Metastatic, Locally-Advanced or Recurrent Solid Tumors
August 25, 2021 07:30 ET
|
XRad Therapeutics, Inc.
- Study to evaluate the safety and tolerability of XRD-0394 in combination with palliative radiation therapy - Major milestone for the company with first asset reaching clinical development ...